• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
SHORT COMMUNICATION
Year : 2016  |  Volume : 2  |  Issue : 2  |  Page : 37-40

Effect of Irinotecan Combined with Cetuximab on Liver Function in Patients with Advanced Colorectal Cancer with Liver Metastases


1 Department of Blood Transfusion, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
2 Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
3 Cancer Research Institute, Southern Medical University, Guangzhou, Guangdong, China
4 Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China

Correspondence Address:
Dr. Yan Liang
Department of Blood Transfusion, The First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2395-3977.181433

Rights and Permissions

Aim: To explore the effect of irinotecan combined with cetuximab on liver function of advanced colorectal cancer patients with liver metastases. Methods: A total of 97 advanced colorectal cancer patients with liver metastases admitted to our hospital from August 2008 to August 2011 were treated with irinotecan combined with cetuximab. Changes of tumor markers, liver metastasis diameter, and liver function were observed, and the response rate was analyzed. Results: After the treatment, carcinoembryonic antigen, carbohydrate antigen 19-9, prothrombin time, albumin, and metastasis diameter significantly decreased (P < 0.05) and aspartate aminotransferase, alanine aminotransferase, and total bilirubin increased significantly (P < 0.05). Average length of stay was 16.2 ± 3.7 weeks. There were 0 case of complete remission, 25 cases of partial response, 41 cases of stable disease, and 31 cases of progressive disease. The response rate was 25.77% and disease control rate was 68.04%. Adverse reactions were present in 92 cases, with the incidence rate of 94.85%. Conclusion: Although the liver function tests show that the damage is caused by irinotecan combined with cetuximab, the normal cells recover and therefore liver function returns to near baseline. The data from this trial suggests that the combination treatment with irinotecan and cetuximab for colorectal cancer patients with liver metastases is safe and effective, resulting in improved prognosis and quality of life.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1477    
    Printed29    
    Emailed0    
    PDF Downloaded162    
    Comments [Add]    

Recommend this journal